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The US Renal Data System (USRDS) remains the largest and most comprehensive resource 
for those seeking detailed information, data, and trends on a wide variety of kidney disease 
topics covering both end-stage renal disease (ESRD) and earlier stages of chronic kidney 
disease (CKD). Supported by the National Institute of Diabetes and Digestive and Kidney 
Diseases (NIDDK) at the National Institutes of Health and the Centers for Medicare & 
Medicaid Services, the USRDS Coordinating Center has operated from the Kidney 
Epidemiology and Cost Center (KECC) at the University of Michigan, in partnership with 
Arbor Research Collaborative for Health, in Ann Arbor, Michigan, since 2014. The annual 
report is published both online (www.usrds.org), and as a supplement to AJKD.
Trends in the prevalence of CKD and ESRD are important for health care policy and 
planning. According to data from the National Health and Nutrition Examination Survey 
(NHANES), the prevalence of CKD among US adults is estimated at just under 15%, 
indicating that over 30 million American adults may have CKD. This is likely due to the 
high prevalence of risk factors for the disease, including an aging population, diabetes, 
hypertension, obesity, cardiovascular disease, and other conditions.
The report highlights the fact that US rates for ESRD (ie, dialysis or transplantation) rank 
among the highest in the world, and continue to rise. In 2016, there were 124,675 new cases 
registered as ESRD, compared to 124,111 new cases the prior year. The prevalence of ESRD 
continues to rise and reached 726,331 in 2016. Additionally, there are many “hot spots” of 
the condition around the country as highlighted in the maps and tables contained in the 
Annual Data Report.
Caring for those with kidney disease is expensive. The total Medicare spending on both 
CKD and ESRD patients was in excess of $114 billion in 2016. Accompanying chronic 
diseases such as diabetes and heart failure compound the cost of caring for these individuals.
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In sharp contrast to this high burden and cost, the USRDS continues to highlight low 
awareness about the presence of the condition among patients with laboratory evidence of 
early stages of kidney disease (CKD stages 1–3). Encouragingly, in recent years, there has 
been some increase in awareness among those with CKD stage 4.
In the newly expanded chapter on hospitalization, the trend in falling hospitalization rates is 
shown to be countered by rising rates of emergency room visits and short-term observation 
stays for those on dialysis. A new chapter on CKD among children and adolescents is 
introduced in the 2018 USRDS Annual Data Report, along with the continued extensive 
coverage of ESRD among children, adolescents, and young adults. The international 
comparisons chapter now includes descriptive ESRD data from over 70 countries. A 
decrease in the kidney transplant waiting list by 3% over 2 successive years is a noteworthy 
observation—very likely the result of recent changes in the kidney allocation system.
We hope that researchers, practitioners, and policy makers will continue to derive value not 
only from the Annual Data Reports, a regularly updated comprehensive resource for 
epidemiology of kidney disease in the nation, but also from the data-provisioning activities 
of the USRDS and assistance to researchers through its help desk.
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